A medical startup aims to shrink terminal cancer
That’s Uzi Sofer’s goal: to deprive the malach hamaves of the deadliest weapon in his arsenal.
Sofer is CEO and cofounder of the Israeli biomedical tech start-up Alpha Tau, and if the company’s clinical testing continues with its already positive results, the grand prize, the most dreaded diagnosis of all, metastatic cancer — stage 4 — could become treatable.
That day could soon be upon us, thanks to the technological leap developed by Sofer’s company, based in Jerusalem’s Har Hotzvim industrial park. The 52-year-old Sofer is under no illusion as to how this came about.
“When you’re sitting in my chair,” he says, “you often need to make decisions when there is no way to know in real time what the right choice is. And maybe after two months — sometimes it’s a year, sometimes it’s a week — you see that you made the right choice, even though you didn’t have all the information you needed to go in the right direction. For me, this is Hashgachah pratit. You get help from Above in those challenging times.”
Create a free account to keep reading.
